P1Y http://fasb.org/us-gaap/2022#FairValueInputsLevel2Member http://www.veeco.com/20230331#AccruedAndOtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent http://www.veeco.com/20230331#AccruedAndOtherLiabilitiesCurrent 0000103145--12-31 2023 Q1 false P5D http://fasb.org/us-gaap/2022#FairValueInputsLevel2Member P1Y http://fasb.org/us-gaap/2022#MeasurementInputDiscountRateMember 0000103145 srt:MinimumMember 2023-01-01 2023-03-31 0000103145 2020-12-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000103145 srt:MaximumMember veco:RevolvingCreditFacilityDecember2021Member 2021-12-16 0000103145 veco:RevolvingCreditFacilityDecember2021Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2021-12-16 0000103145 veco:CertificateOfDepositsAndTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 veco:CertificateOfDepositsAndTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 veco:CertificateOfDepositsAndTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 veco:CertificateOfDepositsAndTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 veco:DerivativeContractCappedCallMember 2020-05-13 0000103145 veco:DerivativeContractCappedCallMember 2020-05-13 2020-05-13 0000103145 veco:EpiluvacAbMember veco:PercentageOfOrdersReceivedDuringEarnOutPeriodMember 2023-01-31 2023-01-31 0000103145 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000103145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000103145 us-gaap:RetainedEarningsMember 2023-03-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000103145 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000103145 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0000103145 us-gaap:RetainedEarningsMember 2022-12-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000103145 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000103145 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000103145 us-gaap:RetainedEarningsMember 2022-03-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000103145 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0000103145 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000103145 us-gaap:RetainedEarningsMember 2021-12-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000103145 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0000103145 us-gaap:CommonStockMember 2023-03-31 0000103145 us-gaap:CommonStockMember 2022-12-31 0000103145 us-gaap:CommonStockMember 2022-03-31 0000103145 us-gaap:CommonStockMember 2021-12-31 0000103145 srt:MinimumMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000103145 srt:MaximumMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000103145 veco:RestrictedAndPerformanceSharesMember 2023-03-31 0000103145 veco:RestrictedAndPerformanceSharesMember 2022-12-31 0000103145 veco:RestrictedAndPerformanceSharesMember 2023-01-01 2023-03-31 0000103145 srt:MinimumMember 2023-04-01 2023-03-31 0000103145 srt:MaximumMember 2023-04-01 2023-03-31 0000103145 2023-04-01 2023-03-31 0000103145 veco:SemiconductorMember 2023-01-01 2023-03-31 0000103145 veco:ScientificAndOtherMember 2023-01-01 2023-03-31 0000103145 veco:RestOfWorldMember 2023-01-01 2023-03-31 0000103145 veco:DataStorageMember 2023-01-01 2023-03-31 0000103145 veco:CompoundSemiconductorMember 2023-01-01 2023-03-31 0000103145 veco:AsiaPacificExcludingChinaMember 2023-01-01 2023-03-31 0000103145 us-gaap:EMEAMember 2023-01-01 2023-03-31 0000103145 country:US 2023-01-01 2023-03-31 0000103145 country:CN 2023-01-01 2023-03-31 0000103145 veco:SemiconductorMember 2022-01-01 2022-03-31 0000103145 veco:ScientificAndOtherMember 2022-01-01 2022-03-31 0000103145 veco:RestOfWorldMember 2022-01-01 2022-03-31 0000103145 veco:DataStorageMember 2022-01-01 2022-03-31 0000103145 veco:CompoundSemiconductorMember 2022-01-01 2022-03-31 0000103145 veco:AsiaPacificExcludingChinaMember 2022-01-01 2022-03-31 0000103145 us-gaap:EMEAMember 2022-01-01 2022-03-31 0000103145 country:US 2022-01-01 2022-03-31 0000103145 country:CN 2022-01-01 2022-03-31 0000103145 us-gaap:MachineryAndEquipmentMember 2023-03-31 0000103145 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000103145 us-gaap:LandMember 2023-03-31 0000103145 us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0000103145 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000103145 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000103145 us-gaap:LandMember 2022-12-31 0000103145 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2017-01-10 2017-01-10 0000103145 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000103145 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000103145 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0000103145 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000103145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000103145 srt:MinimumMember veco:RevolvingCreditFacilityDecember2021Member 2021-12-16 2021-12-16 0000103145 srt:MaximumMember veco:RevolvingCreditFacilityDecember2021Member 2021-12-16 2021-12-16 0000103145 veco:RevolvingCreditFacilityDecember2021Member 2021-12-16 0000103145 veco:RevolvingCreditFacilityDecember2021LetterOfCreditMember 2021-12-16 0000103145 veco:RevolvingCreditFacilityDecember2021Member 2023-01-01 2023-03-31 0000103145 veco:RevolvingCreditFacilityDecember2021Member 2022-01-01 2022-12-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000103145 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000103145 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2021-11-05 0000103145 us-gaap:TrademarksAndTradeNamesMember 2023-03-31 0000103145 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000103145 us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000103145 us-gaap:CustomerRelationshipsMember 2023-03-31 0000103145 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0000103145 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000103145 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000103145 us-gaap:CustomerRelationshipsMember 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2021-11-05 2021-11-05 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2020-11-11 2020-11-11 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2020-05-18 2020-05-18 0000103145 veco:RevolvingCreditFacilityDecember2021Member 2021-12-16 2021-12-16 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2022-12-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2017-01-10 0000103145 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2020-11-17 2020-11-17 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2020-05-18 2020-05-18 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2020-11-17 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2020-05-18 0000103145 srt:MinimumMember veco:RevolvingCreditFacilityDecember2021Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2021-12-16 2021-12-16 0000103145 srt:MinimumMember veco:RevolvingCreditFacilityDecember2021Member us-gaap:BaseRateMember 2021-12-16 2021-12-16 0000103145 srt:MaximumMember veco:RevolvingCreditFacilityDecember2021Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2021-12-16 2021-12-16 0000103145 srt:MaximumMember veco:RevolvingCreditFacilityDecember2021Member us-gaap:BaseRateMember 2021-12-16 2021-12-16 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2023-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2023-03-31 0000103145 2022-03-31 0000103145 2021-12-31 0000103145 us-gaap:OtherLiabilitiesMember veco:EpiluvacAbMember 2023-01-31 0000103145 veco:EpiluvacAbMember 2023-01-31 0000103145 us-gaap:AccountsPayableAndAccruedLiabilitiesMember veco:EpiluvacAbMember 2023-01-31 0000103145 veco:EpiluvacAbMember veco:PercentageOfOrdersReceivedDuringEarnOutPeriodMember 2023-01-31 0000103145 veco:EpiluvacAbMember veco:CompletionOfMilestonesMember 2023-01-31 0000103145 veco:EpiluvacAbMember 2023-01-31 2023-01-31 0000103145 us-gaap:CommercialPaperMember 2023-03-31 0000103145 us-gaap:CommercialPaperMember 2022-12-31 0000103145 us-gaap:USTreasurySecuritiesMember 2023-03-31 0000103145 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000103145 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000103145 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0000103145 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000103145 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0000103145 us-gaap:OtherLiabilitiesMember 2023-03-31 0000103145 us-gaap:OtherLiabilitiesMember 2022-12-31 0000103145 veco:PotentiallyDilutiveSharesMember 2023-01-01 2023-03-31 0000103145 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000103145 veco:PotentiallyDilutiveSharesMember 2022-01-01 2022-03-31 0000103145 us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2023-01-01 2023-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2023-01-01 2023-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2023-01-01 2023-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2027Member 2022-01-01 2022-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2025Member 2022-01-01 2022-03-31 0000103145 veco:ConvertibleSeniorUnsecuredNotesDue2023Member 2022-01-01 2022-03-31 0000103145 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000103145 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0000103145 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000103145 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000103145 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000103145 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000103145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000103145 2022-01-01 2022-03-31 0000103145 veco:EpiluvacAbMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-31 2023-01-31 0000103145 veco:EpiluvacAbMember us-gaap:OrderOrProductionBacklogMember 2023-01-31 2023-01-31 0000103145 veco:EpiluvacAbMember us-gaap:CustomerRelationshipsMember 2023-01-31 2023-01-31 0000103145 2023-03-31 0000103145 2022-12-31 0000103145 2023-05-02 0000103145 2023-01-01 2023-03-31 xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares veco:D veco:segment veco:item

Table of Contents

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 10-Q

(Mark One)

​

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended March 31, 2023

OR

​

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-16244

VEECO INSTRUMENTS INC.

(Exact Name of Registrant as Specified in Its Charter)

​

​ | ​ | ​
Delaware |  | 11-2989601
(State or Other Jurisdiction of Incorporation or Organization) | ​ | (I.R.S. Employer Identification No.)
​ | ​ | ​
Terminal Drive Plainview, New York | ​ | 11803
(Address of Principal Executive Offices) | ​ | (Zip Code)

​

Registrant’s telephone number, including area code:

(516) 677-0200

Securities registered pursuant to Section 12(b) of the Act:

​

​ ​ ​ ​ ​ |  |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.01 per share | VECO | The NASDAQ Global Select Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ◻

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☒ No ◻

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

​ | ​ | ​ | ​ | ​
Large accelerated filer ☒ |  | ​ |  | Accelerated filer ☐
Non-accelerated filer ☐ | ​ | ​ | ​ | Smaller reporting company ☐
​ | ​ | ​ | ​ | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

​

As of May 2, 2023, there were 51,692,973 shares of the registrant’s common stock outstanding.

​

​

​

​

​

Table of Contents

VEECO INSTRUMENTS INC.

​

INDEX

​

Safe Harbor Statement | 1
​ | ​
PART I—FINANCIAL INFORMATION | 4
​ | ​
Item 1. Financial Statements | 4
​ | ​
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 29
​ | ​
Item 3. Quantitative and Qualitative Disclosures about Market Risk | 35
​ | ​
Item 4. Controls and Procedures | 35
​ | ​
PART II—OTHER INFORMATION | 36
​ | ​
Item 1. Legal Proceedings | 36
​ | ​
Item 1A. Risk Factors | 36
​ | ​
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 36
​ | ​
Item 3. Defaults Upon Senior Securities | 36
​ | ​
Item 4. Mine Safety Disclosures | 36
​ | ​
Item 5. Other Information | 36
​ | ​
Item 6. Exhibits | 37
​ | ​
SIGNATURES | 38

​

​

​

​

Table of Contents

Safe Harbor Statement

​

This quarterly report on Form 10-Q (the “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Discussions containing such forward-looking statements may be found in Part I - Items 1, 2, and 3 hereof, as well as within this Report generally. In addition, when used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “targets,” “plans,” “intends,” “will,” and similar expressions related to the future are intended to identify forward-looking statements. All forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from projected results.

​

In addition, the preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates and assumptions are based on knowledge of current events, including the potential impact of the COVID-19 pandemic on our business, and planned actions to be undertaken in the future, they may ultimately differ from actual results. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. All estimates and assumptions are subject to a number of risks and uncertainties that could cause actual results to differ materially from these estimates and assumptions.

​

The risks and uncertainties of Veeco Instruments Inc. (together with its consolidated subsidiaries, “Veeco,” the “Company,” “we,” “us,” and “our,” unless the context indicates otherwise) include, without limitation, those set forth under the heading “Risk Factors” in Part 1, Item 1A of our 2022 Form 10-K, and the following:

​

Risks Related to Our Business and Industry

​

| ● | Unfavorable market conditions have adversely affected, and may continue to adversely affect, our operating results;

​

| ● | We face significant competition;

​

| ● | We operate in industries characterized by rapid technological change;

​

| ● | Certain of our sales are dependent on the demand for consumer electronic products and automobiles, which can experience significant volatility;

​

| ● | The effects of the COVID-19 pandemic have strained and have negatively impacted our businesses and operations, and the duration and extent to which COVID-19 may impact our future results of operations and overall financial performance remains uncertain;

​

| ● | We have a concentrated customer base, located primarily in a limited number of regions, which operates in highly concentrated industries;

​

| ● | The cyclicality of the industries we serve directly affects our business;

​

| ● | Our failure to estimate customer demand accurately could result in inventory obsolescence, liabilities to our suppliers for products no longer needed, and manufacturing interruptions or delays which could affect our ability to meet customer demand;

​

1

Table of Contents

​

| ● | We rely on a limited number of suppliers, some of whom are our sole source for particular components;

​

| ● | Our failure to successfully manage our outsourcing activities or failure of our outsourcing partners to perform as anticipated could adversely affect our results of operations;

​

| ● | The timing of our orders, shipments, and revenue recognition may cause our quarterly operating results to fluctuate significantly;

​

| ● | Our sales cycle is long and unpredictable;

​

| ● | Our backlog is subject to customer cancellation or modification which could result in decreased sales, increased inventory obsolescence, and liabilities to our suppliers for products no longer needed;

​

| ● | We are exposed to risks associated with business combinations, acquisitions, strategic investments and divestitures;

​

Risks Associated with Operating a Global Business

​

| ● | We are exposed to risks of operating businesses outside the United States;

​

| ● | Changes in U.S. trade policy and export controls and ongoing trade disputes between the U.S. and China have adversely affected, and may continue to adversely affect, our business, results of operations, and financial condition;

​

| ● | We may be unable to obtain required export licenses for the sale of our products;

​

| ● | We are exposed to various risks associated with global regulatory requirements;

​

Risks Related to Intellectual Property and Cybersecurity

​

| ● | Disruptions in our information technology systems or data security incidents could result in significant financial, legal, regulatory, business, and reputational harm to us;

​

| ● | We may be unable to effectively enforce and protect our intellectual property rights;

​

| ● | We may be subject to claims of intellectual property infringement by others;

​

Financial, Accounting, and Capital Markets Risks

​

| ● | Our operating results may be adversely affected by tightening credit markets;

​

| ● | We are subject to foreign currency exchange risks;

​

| ● | We may be required to take impairment charges on assets;

​

| ● | Changes in accounting pronouncements or taxation rules, practices, or rates may adversely affect our financial results;

​

| ● | Our current debt facilities, including our 3.50% Convertible Senior Notes due 2025 (the “2025 Notes”), and our 3.75% Convertible Senior Notes due 2027 (the “2027 Notes”) (the 2025 Notes, and 2027 Notes, together, the “Notes”), and our revolving credit facility (the “Credit Facility”), may contain certain restrictions, covenants and repurchase provisions that may limit our ability to raise the funds necessary to meet our working capital

2

Table of Contents

|  | needs, which may include the cash conversion of the Notes or repurchase of the Notes for cash upon a fundamental change;

​

| ● | Issuance of our common stock, if any, upon conversion of the Notes, as well as the capped call transactions and the hedging activities of the option counterparties, may impair or reduce our ability to utilize our foreign tax credits or our research and development credits carryforwards in the future;

​

| ● | The capped call transactions may affect the value of the 2027 Notes and our common stock;

​

General Risk Factors

​

| ● | The price of our common shares is volatile and could decrease;

​

| ● | Our inability to attract, retain, and motivate employees could have a material adverse effect on our business;

​

| ● | We are subject to risks of non-compliance with environmental, health, and safety regulations and sustainability requirements;

​

| ● | We are exposed to risks associated with the increased attention by our stakeholders to environmental, social and governance (“ESG”) matters; and

​

| ● | We have adopted certain measures that may have anti-takeover effects which may make an acquisition of our Company by another company more difficult.

​

Consequently, such forward looking statements and estimates should be regarded solely as the current plans and beliefs of Veeco. We do not undertake any obligation to update any forward looking statements to reflect future events or circumstances after the date of such statements.

​

3

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

Veeco Instruments Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share amounts)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2023 |  | 2022
Assets | ​ | (unaudited) | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 140,721 | ​ | $ | 154,925
Restricted cash | ​ | ​ | 476 | ​ | ​ | 547
Short-term investments | ​ |  | 112,170 | ​ |  | 147,488
Accounts receivable, net | ​ |  | 120,091 | ​ |  | 124,221
Contract assets | ​ | ​ | 17,727 | ​ | ​ | 16,507
Inventories | ​ |  | 225,717 | ​ |  | 206,908
Prepaid expenses and other current assets | ​ | ​ | 26,368 | ​ | ​ | 18,305
Total current assets | ​ |  | 643,270 | ​ |  | 668,901
Property, plant, and equipment, net | ​ |  | 113,228 | ​ |  | 107,281
Operating lease right-of-use assets | ​ | ​ | 26,279 | ​ | ​ | 26,467
Intangible assets, net | ​ | ​ | 50,316 | ​ | ​ | 23,887
Goodwill | ​ |  | 214,964 | ​ |  | 181,943
Deferred income taxes | ​ | ​ | 115,949 | ​ | ​ | 116,349
Other assets | ​ |  | 3,242 | ​ |  | 3,355
Total assets | ​ | $ | 1,167,248 | ​ | $ | 1,128,183
​ | ​ | ​ | ​ | ​ | ​ | ​
Liabilities and stockholders' equity | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 61,973 | ​ | $ | 52,049
Accrued expenses and other current liabilities | ​ |  | 69,490 | ​ |  | 56,031
Customer deposits and deferred revenue | ​ |  | 133,187 | ​ |  | 127,223
Income taxes payable | ​ |  | 2,525 | ​ |  | 2,432
Current portion of long-term debt | ​ |  | — | ​ |  | 20,169
Total current liabilities | ​ |  | 267,175 | ​ |  | 257,904
Deferred income taxes | ​ |  | 6,938 | ​ |  | 1,285
Long-term debt | ​ |  | 254,713 | ​ |  | 254,491
Long-term operating lease liabilities | ​ | ​ | 33,513 | ​ | ​ | 33,581
Other liabilities | ​ |  | 19,350 | ​ |  | 3,098
Total liabilities | ​ |  | 581,689 | ​ |  | 550,359
Stockholders' equity: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $0.01 par value; 500,000 shares authorized; no shares issued and outstanding. | ​ |  | — | ​ | ​ | —
Common stock, $0.01 par value; 120,000,000 shares authorized; 51,692,973 shares issued and outstanding at March 31, 2023 and 51,660,409 shares issued and outstanding at December 31, 2022 | ​ |  | 517 | ​ |  | 517
Additional paid-in capital | ​ |  | 1,076,698 | ​ |  | 1,078,180
Accumulated deficit | ​ |  | (493,060) | ​ |  | (501,801)
Accumulated other comprehensive income | ​ |  | 1,404 | ​ |  | 928
Total stockholders' equity | ​ |  | 585,559 | ​ |  | 577,824
Total liabilities and stockholders' equity | ​ | $ | 1,167,248 | ​ | $ | 1,128,183

​

See accompanying Notes to the Consolidated Financial Statements.

​

​

​

4

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three months ended March 31, | ​
​ |  |  | 2023 |  | 2022 |
Net sales | ​ | ​ | $ | 153,504 | ​ | $ | 156,426 | ​
Cost of sales | ​ | ​ |  | 91,487 | ​ |  | 90,413 | ​
Gross profit | ​ | ​ | ​ | 62,017 | ​ | ​ | 66,013 | ​
Operating expenses, net: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | ​ |  | 27,562 | ​ |  | 24,117 | ​
Selling, general, and administrative | ​ | ​ |  | 22,627 | ​ |  | 22,894 | ​
Amortization of intangible assets | ​ | ​ |  | 2,111 | ​ |  | 2,504 | ​
Other operating expense (income), net | ​ | ​ | ​ | (89) | ​ | ​ | (19) | ​
Total operating expenses, net | ​ | ​ | ​ | 52,211 | ​ | ​ | 49,496 | ​
Operating income | ​ | ​ |  | 9,806 | ​ |  | 16,517 | ​
Interest income | ​ | ​ |  | 2,073 | ​ |  | 89 | ​
Interest expense | ​ | ​ |  | (2,875) | ​ |  | (2,892) | ​
Income before income taxes | ​ | ​ | ​ | 9,004 | ​ | ​ | 13,714 | ​
Income tax expense (benefit) | ​ | ​ |  | 263 | ​ |  | 384 | ​
Net income | ​ | ​ | $ | 8,741 | ​ | $ | 13,330 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income per common share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | $ | 0.17 | ​ | $ | 0.27 | ​
Diluted | ​ | ​ | $ | 0.17 | ​ | $ | 0.24 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average number of shares: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ |  | 50,559 | ​ |  | 49,614 | ​
Diluted | ​ | ​ |  | 59,856 | ​ |  | 65,285 | ​

​

See accompanying Notes to the Consolidated Financial Statements.

​

5

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income

(in thousands)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​
​ |  | 2023 |  | 2022 |
Net income | ​ | $ | 8,741 | ​ | $ | 13,330 | ​
Other comprehensive income (loss), net of tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Unrealized gain (loss) on available-for-sale securities | ​ |  | 470 | ​ |  | (819) | ​
Change in currency translation adjustments | ​ |  | 6 | ​ |  | (3) | ​
Total other comprehensive income (loss), net of tax | ​ |  | 476 | ​ |  | (822) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total comprehensive income | ​ | $ | 9,217 | ​ | $ | 12,508 | ​

​

See accompanying Notes to the Consolidated Financial Statements.

​

6

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​
​ |  | 2023 |  | 2022 |
Cash Flows from Operating Activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 8,741 | ​ | $ | 13,330 | ​
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 6,276 | ​ |  | 6,240 | ​
Non-cash interest expense | ​ | ​ | 226 | ​ | ​ | 238 | ​
Deferred income taxes | ​ |  | 191 | ​ |  | (16) | ​
Share-based compensation expense | ​ |  | 7,027 | ​ |  | 4,481 | ​
Changes in operating assets and liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable and contract assets | ​ |  | 3,157 | ​ |  | 2,821 | ​
Inventories | ​ |  | (25,763) | ​ |  | (8,254) | ​
Prepaid expenses and other current assets | ​ |  | (4,783) | ​ |  | (8,240) | ​
Accounts payable and accrued expenses | ​ |  | 13,431 | ​ |  | 14,773 | ​
Customer deposits and deferred revenue | ​ |  | 5,534 | ​ |  | (1,243) | ​
Income taxes receivable and payable, net | ​ |  | 94 | ​ |  | (228) | ​
Other, net | ​ |  | (213) | ​ |  | 886 | ​
Net cash provided by (used in) operating activities | ​ |  | 13,918 | ​ |  | 24,788 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash Flows from Investing Activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Capital expenditures | ​ |  | (6,946) | ​ |  | (10,918) | ​
Acquisition of Businesses, net of cash acquired | ​ | ​ | (30,373) | ​ | ​ | — | ​
Proceeds from the sale of investments | ​ |  | 40,049 | ​ |  | 2,260 | ​
Payments for purchases of investments | ​ |  | (3,492) | ​ |  | (2,498) | ​
Net cash provided by (used in) investing activities | ​ | ​ | (762) | ​ | ​ | (11,156) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash Flows from Financing Activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Proceeds (net of tax withholdings) from option exercises and employee stock purchase plan | ​ |  | 1,241 | ​ |  | 998 | ​
Restricted stock tax withholdings | ​ |  | (8,509) | ​ |  | (6,787) | ​
Repayment of 2023 Notes | ​ | ​ | (20,173) | ​ | ​ | — | ​
Net cash provided by (used in) financing activities | ​ |  | (27,441) | ​ |  | (5,789) | ​
Effect of exchange rate changes on cash and cash equivalents | ​ |  | 10 | ​ |  | (3) | ​
Net increase (decrease) in cash, cash equivalents, and restricted cash | ​ |  | (14,275) | ​ |  | 7,840 | ​
Cash, cash equivalents, and restricted cash - beginning of period | ​ |  | 155,472 | ​ |  | 120,472 | ​
Cash, cash equivalents, and restricted cash - end of period | ​ | $ | 141,197 | ​ | $ | 128,312 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental Disclosure of Cash Flow Information | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest paid | ​ | $ | 2,744 | ​ | $ | 2,593 | ​
Income taxes paid (refunds received) | ​ | ​ | 386 | ​ | ​ | 523 | ​
Non-cash activities | ​ | ​ | ​ | ​ | ​ | ​ | ​
Capital expenditures included in accounts payable and accrued expenses | ​ | ​ | 5,052 | ​ | ​ | 6,253 | ​
Net transfer of inventory to property, plant and equipment | ​ | ​ | 4,304 | ​ | ​ | 46 | ​
Right-of-use assets obtained in exchange for lease obligations | ​ | ​ | 630 | ​ | ​ | 258 | ​

​

See accompanying Notes to the Consolidated Financial Statements.

​

7

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(unaudited)

​

Note 1 — Basis of Presentation

​

The accompanying unaudited Consolidated Financial Statements of Veeco have been prepared in accordance with U.S. GAAP as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 270 for interim financial information and with the instructions to Rule 10-01 of Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as the interim information is an update of the information that was presented in Veeco’s most recent annual financial statements. For further information, refer to Veeco’s Consolidated Financial Statements and Notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2022 (“2022 Form 10-K”). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal, recurring nature.

​

Veeco reports interim quarters on a 13-week basis ending on the last Sunday of each quarter. The fourth quarter always ends on the last day of the calendar year, December 31. The 2023 interim quarters end on April 2, July 2, and October 1, and the 2022 interim quarters ended on April 3, July 3, and October 2. These interim quarters are reported as March 31, June 30, and September 30 in Veeco’s interim consolidated financial statements.

​

The preparation of financial statements in conformity with U.S GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates.

​

Revenue Recognition

​

Revenue is recognized upon the transfer of control of the promised product or service to the customer in an amount that reflects the consideration the Company expects to receive in exchange for such product or service. The Company’s contracts with customers generally do not contain variable consideration. In the rare instances where variable consideration is included, the Company estimates the amount of variable consideration and determines what portion of that, if any, has a high probability of significant subsequent revenue reversal, and if so, that amount is excluded from the transaction price. The Company’s contracts with customers frequently contain multiple deliverables, such as systems, upgrades, components, spare parts, installation, maintenance, and service plans. Judgment is required to properly identify the performance obligations within a contract and to determine how the revenue should be allocated among the performance obligations. The Company also evaluates whether multiple transactions with the same customer or related parties should be considered part of a single contract based on an assessment of whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of one another.

When there are separate units of accounting, the Company allocates revenue to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling prices are determined based on the prices at which the Company separately sells the systems, upgrades, components, spare parts, installation, maintenance, and service plans. For items that are not sold separately, the Company estimates stand-alone selling prices generally using an expected cost plus margin approach.

Most of the Company’s revenue is recognized at a point in time when the performance obligation is satisfied. The Company considers many facts when evaluating each of its sales arrangements to determine the timing of revenue recognition, including its contractual obligations and the nature of the customer’s post-delivery acceptance provisions. The Company’s system sales arrangements, including certain upgrades, generally include field acceptance provisions that may include functional or mechanical test procedures. For many of these arrangements, a customer source inspection of the system is performed in the Company’s facility, test data is sent to the customer documenting that the system is functioning to the agreed upon specifications prior to delivery, or other quality assurance testing is performed

8

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

internally to ensure system functionality prior to shipment. Historically, such source inspection or test data replicates the field acceptance provisions that are performed at the customer’s site prior to final acceptance of the system. When the Company objectively demonstrates that the criteria specified in the contractual acceptance provisions are achieved prior to delivery either through customer testing or the Company’s historical experience of its tools meeting specifications, transfer of control of the product to the customer is considered to have occurred and revenue is recognized upon system delivery since there is no substantive contingency remaining related to the acceptance provisions at that date. For new products, new applications of existing products, or for products with substantive customer acceptance provisions where the Company cannot objectively demonstrate that the criteria specified in the contractual acceptance provisions have been achieved prior to delivery, revenue and the associated costs are deferred. The Company recognizes such revenue and costs upon obtaining objective evidence that the acceptance provisions can be achieved, assuming all other revenue recognition criteria have been met.

In certain cases the Company’s contracts with customers contain a billing retention, which is billed by the Company and payable by the customer when field acceptance provisions are completed. Revenue recognized in advance of the amount that has been billed is recorded as a contract asset on the Consolidated Balance Sheets.

The Company recognizes revenue related to maintenance and service contracts over time based upon the respective contract term. Installation revenue is recognized over time as the installation services are performed. The Company recognizes revenue from the sales of components, spare parts, and specified service engagements at a point in time, which is typically consistent with the time of delivery in accordance with the terms of the applicable sales arrangement.

The Company may receive customer deposits on system transactions. The timing of the transfer of goods or services related to the deposits is either at the discretion of the customer or generally expected to be within one year from the deposit receipt. As such, the Company does not adjust transaction prices for the time value of money. Incremental direct costs incurred related to the acquisition of a customer contract, such as sales commissions, are expensed as incurred since the expected amortization period is one year or less.

​

The Company has elected to treat shipping and handling costs as a fulfillment activity, and the Company includes such costs in cost of sales when the Company recognizes revenue for the related goods. Taxes assessed by governmental authorities that are collected by the Company from a customer are excluded from revenue.

​

Inventories

​

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Each quarter the Company assesses the valuation and recoverability of all inventories: materials (raw materials, spare parts, and service inventory); work-in-process; and finished goods. Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made. Inventory acquired as part of a business combination is recorded at fair value on the date of acquisition.

​

9

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Note 2 — Income Per Common Share

​

Basic income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted income per share is calculated by dividing net income available to common shareholders by the weighted average number of shares used to calculate basic income per share plus the weighted average number of common share equivalents outstanding during the period. The dilutive effect of outstanding options to purchase common stock and share-based awards is considered in diluted income per share by application of the treasury stock method. The dilutive effect of performance share units is included in diluted income per common share if the performance targets have been achieved, or would have been achieved if the reporting date was the end of the contingency period. Finally, the Company includes the dilutive effect of shares issuable upon conversion of its Notes in the calculation of diluted income per share using the if-converted method. The computations of basic and diluted income per share for the three months ended March 31, 2023 and 2022 are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​ | ​
​ |  | 2023 |  | 2022 |  |
​ | ​ | (in thousands, except per share amounts) | ​
Numerator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 8,741 | ​ | $ | 13,330 | ​ | ​
Interest expense associated with convertible notes | ​ | ​ | 1,277 | ​ | ​ | 2,544 | ​ | ​
Net income available to common shareholders | ​ | $ | 10,018 | ​ | $ | 15,874 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Denominator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic weighted average shares outstanding | ​ |  | 50,559 | ​ |  | 49,614 | ​ | ​
Effect of potentially dilutive share-based awards | ​ | ​ | 355 | ​ | ​ | 1,208 | ​ | ​
Dilutive effect of convertible notes | ​ |  | 8,942 | ​ |  | 14,463 | ​ | ​
Diluted weighted average shares outstanding | ​ |  | 59,856 | ​ |  | 65,285 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income per common share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | $ | 0.17 | ​ | $ | 0.27 | ​ | ​
Diluted | ​ | $ | 0.17 | ​ | $ | 0.24 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Potentially dilutive shares excluded from the diluted calculation as their effect would be antidilutive | ​ | ​ | 1,140 | ​ | ​ | 613 | ​ | ​
Maximum potential shares to be issued for settlement of the convertible notes excluded from the diluted calculation as their effect would be antidilutive | ​ | ​ | 5,603 | ​ | ​ | 504 | ​ | ​

​

​

Note 3 — Business Combination

​

Epiluvac

​

On January 31, 2023, the Company acquired Epiluvac AB, a privately held manufacturer of chemical vapor deposition (CVD) epitaxy systems that enable silicon carbide (SiC) applications in the electric vehicle market. This acquisition is expected to accelerate penetration into the emerging, high-growth SiC equipment market. The results of Epiluvac’s operations have been included in the consolidated financial statements since the date of acquisition.

​

10

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

The acquisition date fair value of the consideration totaled $56.4 million, net of cash acquired, which consisted of the following:

​

​ | ​ | ​ | ​
​ |  | Acquisition Date
​ | ​ | (January 31, 2023)
​ | ​ | (in thousands)
Cash paid, net of cash acquired | ​ | $ | 30,373
Contingent consideration | ​ | ​ | 26,055
Acquisition date fair value | ​ | $ | 56,428

​

The purchase agreement included performance milestones that, if achieved, could trigger additional payments to the original selling shareholders. The aggregate fair value of the contingent consideration arrangement at the acquisition date was $26.1 million, of which $9.6 million was included in “Accrued expenses and other current liabilities” and $16.5 million was included within “Other liabilities” on the Consolidated Balance Sheet as of March 31, 2023. The contingent arrangements include payments up to $15.0 million based on the timely completion of certain defined milestones tied to strategic targets, and up to $20.0 million based on the percentage of orders received during the defined Earn-out period. The Earn-out period is four years after the closing date of the acquisition, or earlier if certain conditions are met.

​

The Company estimated the fair value of the contingent consideration by assigning probabilities and discount factors to each of the various defined performance milestones, while using a Monte-Carlo simulation model to determine the most likely outcome for payments to be based on value of orders received. These fair value measurements are based on significant inputs not observable in the market and thus represent a Level 3 measurement as defined in ASC 820. The discount rate used was 5.54% for the strategic target and order value related contingent payments. The rate was determined based on the nature of the milestone, the risks and uncertainties involved and the time period until the milestone was measured. The determination of the various probabilities and discount factors is highly subjective, requires significant judgment and is influenced by a number of factors, including the adoption of SiC technology. While the use of SiC is expected to grow in the near future, it is difficult to predict the rate at which SiC will be adopted by the market and thus would impact the sales of our equipment.

​

11

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The amounts below are preliminary and are subject to change during the measurement period, not to exceed one year from the acquisition date:

​

​ | ​ | ​ | ​
​ |  | Acquisition Date
​ | ​ | (January 31, 2023)
​ | ​ | (in thousands)
Accounts receivable | ​ | $ | 247
Inventories | ​ |  | 391
Prepaid expense and other current assets | ​ |  | 381
Property, plant, and equipment | ​ |  | 736
Intangible assets | ​ | ​ | 28,540
Total identifiable assets acquired | ​ |  | 30,295
​ | ​ | ​ | ​
Accounts payable and accrued expenses | ​ | ​ | 656
Customer deposits and deferred revenue | ​ | ​ | 429
Deferred income taxes | ​ | ​ | 5,723
Other liabilities | ​ | ​ | 80
Total liabilities assumed | ​ |  | 6,888
​ | ​ | ​ | ​
Net identifiable assets acquired | ​ |  | 23,407
Goodwill | ​ |  | 33,021
Net assets acquired | ​ | $ | 56,428

​

The gross contractual value of the acquired accounts receivable is the amount expected to be collected by the Company, and therefore is also considered its fair value. Goodwill generated from the acquisition is primarily attributed to expected synergies from future growth and strategic advantages provided through the expansion of product offerings as well as assembled workforce and is not expected to be deductible for income tax purposes.

​

The classes of intangible assets acquired, and the estimated useful life of each class is presented in the table below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Acquisition Date
​ | ​ | (January 31, 2023)
​ |  | Amount |  | Useful life
​ | ​ | (in thousands) | ​ | ​ | ​
Technology | ​ | $ | 28,020 |  | 15 | years
Customer relationships | ​ |  | 460 |  | 5 | years
Backlog | ​ | ​ | 60 | ​ | 1.5 | years
Intangible assets acquired | ​ | $ | 28,540 | ​ | ​ | ​

​

The Company determined the estimated fair value of the identifiable intangible assets based on various factors including cost, discounted cash flow, income method, loss-of-revenue/income method, and relief-from-royalty method in determining the purchase price allocation. The estimates are subject to change upon the finalization of the valuation analyses and if additional information about facts and circumstances that existed at the acquisition date become available during the measurement period.

​

For the three months ended March 31, 2023, the Company incurred approximately $0.7 million of acquisition related costs, included within “Selling, general, and administrative” in the Consolidated Statement of Operations. Epiluvac’s results of operations were immaterial to the Company’s Consolidated Statement of Operations for the three months ended March 31, 2023. Additionally, the pro forma Consolidated Statement of Operations as if Epiluvac had been

12

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

acquired as of January 1, 2022 would not be materially different from the Company’s actual Consolidated Statement of Operations for the three months ended March 31, 2023 or 2022.

​

Note 4 — Assets

​

Investments

​

Short-term investments are generally classified as available-for-sale and reported at fair value, with unrealized gains and losses, net of tax, presented as a separate component of stockholders’ equity under the caption “Accumulated other comprehensive income” in the Consolidated Balance Sheets. These securities may include U.S. treasuries, government agency securities, corporate debt, and commercial paper, all with maturities of greater than three months when purchased. All realized gains and losses and unrealized losses resulting from declines in fair value that are other than temporary are included in “Other operating expense (income), net” in the Consolidated Statements of Operations.

​

Fair value is the price that would be received for an asset or the amount paid to transfer a liability in an orderly transaction between market participants. Veeco classifies certain assets based on the following fair value hierarchy:

​

Level 1: Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;

​

Level 2: Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; and

​

Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

​

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Veeco has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions or estimation methodologies could have a significant effect on the estimated fair value amounts.

​

13

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

The following table presents the portion of Veeco’s assets that were measured at fair value on a recurring basis at March 31, 2023 and December 31, 2022:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
​ | ​ | (in thousands)
March 31, 2023 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Certificate of deposits and time deposits | ​ | $ | 50,076 | ​ | $ | — | ​ | $ | — | ​ | $ | 50,076
Money market cash | ​ | ​ | 47,128 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 47,128
Total | ​ | $ | 97,204 | ​ | $ | — | ​ | $ | — | ​ | $ | 97,204
Short-term investments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 38,741 | ​ | $ | — | ​ | $ | — | ​ | $ | 38,741
Government agency securities | ​ | ​ | — | ​ | ​ | 26,263 | ​ | ​ | — | ​ | ​ | 26,263
Corporate debt | ​ | ​ | — | ​ | ​ | 31,294 | ​ | ​ | — | ​ | ​ | 31,294
Commercial paper | ​ | ​ | — | ​ | ​ | 15,872 | ​ | ​ | — | ​ | ​ | 15,872
Total | ​ | $ | 38,741 | ​ | $ | 73,429 | ​ | $ | — | ​ | $ | 112,170
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, 2022 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Certificate of deposits and time deposits | ​ | $ | 61,135 | ​ | $ | — | ​ | $ | — | ​ | $ | 61,135
Money market cash | ​ | ​ | 405 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 405
Total | ​ | $ | 61,540 | ​ | $ | — | ​ | $ | — | ​ | $ | 61,540
Short-term investments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 62,849 | ​ | $ | — | ​ | $ | — | ​ | $ | 62,849
Government agency securities | ​ | ​ | — | ​ | ​ | 27,366 | ​ | ​ | — | ​ | ​ | 27,366
Corporate debt | ​ | ​ | — | ​ | ​ | 41,591 | ​ | ​ | — | ​ | ​ | 41,591
Commercial paper | ​ | ​ | — | ​ | ​ | 15,682 | ​ | ​ | — | ​ | ​ | 15,682
Total | ​ | $ | 62,849 | ​ | $ | 84,639 | ​ | $ | — | ​ | $ | 147,488

​

There were no transfers between fair value measurement levels during the three months ended March 31, 2023.

​

14

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

At March 31, 2023 and December 31, 2022, the amortized cost and fair value of available-for-sale securities consist of:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | ​ |  | Gross |  | Gross |  | ​
​ | ​ | Amortized | ​ | Unrealized | ​ | Unrealized | ​ | Estimated
​ | ​ | Cost | ​ | Gains | ​ | Losses | ​ | Fair Value
​ | ​ | (in thousands)
March 31, 2023 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 38,929 | ​ | $ | — | ​ | $ | (188) | ​ | $ | 38,741
Government agency securities | ​ | ​ | 26,295 | ​ | ​ | 8 | ​ | ​ | (40) | ​ | ​ | 26,263
Corporate debt | ​ | ​ | 31,462 | ​ | ​ | — | ​ | ​ | (168) | ​ | ​ | 31,294
Commercial paper | ​ | ​ | 15,872 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,872
Total | ​ | $ | 112,558 | ​ | $ | 8 | ​ | $ | (396) | ​ | $ | 112,170
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, 2022 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 63,331 | ​ | $ | — | ​ | $ | (482) | ​ | $ | 62,849
Government agency securities | ​ | ​ | 27,464 | ​ | ​ | — | ​ | ​ | (98) | ​ | ​ | 27,366
Corporate debt | ​ |  | 42,006 | ​ | ​ | — | ​ | ​ | (415) | ​ |  | 41,591
Commercial paper | ​ | ​ | 15,682 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 15,682
Total | ​ | $ | 148,483 | ​ | $ | — | ​ | $ | (995) | ​ | $ | 147,488

​

Available-for-sale securities in a loss position at March 31, 2023 and December 31, 2022 consist of:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Continuous Loss Position | ​ | Continuous Loss Position
​ | ​ | for Less than 12 Months | ​ | for 12 Months or More
​ |  | ​ | ​ |  | Gross |  | ​ | ​ |  | Gross
​ | ​ | Estimated | ​ | Unrealized | ​ | Estimated | ​ | Unrealized
​ | ​ | Fair Value | ​ | Losses | ​ | Fair Value | ​ | Losses
​ | ​ | ​ | (in thousands)
March 31, 2023 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 26,462 | ​ | $ | (20) | ​ | $ | 12,279 | ​ | $ | (168)
Government agency securities | ​ | ​ | 24,255 | ​ | ​ | (40) | ​ | ​ | — | ​ | ​ | —
Corporate debt | ​ |  | 17,123 | ​ |  | (85) | ​ |  | 14,171 | ​ |  | (83)
Total | ​ | $ | 67,840 | ​ | $ | (145) | ​ | $ | 26,450 | ​ | $ | (251)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, 2022 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasuries | ​ | $ | 39,791 | ​ | $ | (84) | ​ | $ | 23,057 | ​ | $ | (398)
Government agency securities | ​ | ​ | 22,528 | ​ | ​ | (86) | ​ | ​ | 4,838 | ​ | ​ | (12)
Corporate debt | ​ |  | 19,693 | ​ |  | (138) | ​ |  | 21,898 | ​ |  | (277)
Total | ​ | $ | 82,012 | ​ | $ | (308) | ​ | $ | 49,793 | ​ | $ | (687)

​

The contractual maturities of securities classified as available-for-sale at March 31, 2023 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, 2023
​ | ​ | Amortized | ​ | Estimated
​ | ​ | Cost | ​ | Fair Value
​ | ​ | ​ | (in thousands)
Due in one year or less | ​ | $ | 109,067 | ​ | $ | 108,704
Due after one year through two years | ​ | ​ | 3,491 | ​ |  | 3,466
Total | ​ | $ | 112,558 | ​ | $ | 112,170

​

15

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. There were no realized gains or losses, or unrealized losses from declines in fair value that are other than temporary, for the three months ended March 31, 2023 and 2022.

​

Accounts Receivable

​

Accounts receivable is presented net of an allowance for doubtful accounts of $0.7 million at March 31, 2023 and December 31, 2022. The Company considered its current expectations of future economic conditions when estimating its allowance for doubtful accounts.

​

Inventories

​

Inventories at March 31, 2023 and December 31, 2022 consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2023 |  | 2022
​ | ​ | (in thousands)
Materials | ​ | $ | 143,124 | ​ | $ | 134,940
Work-in-process | ​ |  | 73,676 | ​ |  | 68,765
Finished goods | ​ |  | 8,917 | ​ |  | 3,203
Total | ​ | $ | 225,717 | ​ | $ | 206,908

​

Prepaid Expenses and Other Current Assets

​

Prepaid expenses and other current assets primarily consist of supplier deposits, prepaid value-added tax, lease deposits, prepaid insurance, prepaid licenses, and other receivables. In addition, Veeco had deposits with its suppliers of $13.3 million and $9.4 million at March 31, 2023 and December 31, 2022, respectively.

​

Property, Plant, and Equipment

​

Property, plant, and equipment at March 31, 2023 and December 31, 2022 consist of the following:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2023 |  | 2022
​ | ​ | (in thousands)
Land | ​ | $ | 5,061 | ​ | $ | 5,061
Building and improvements | ​ |  | 64,198 | ​ |  | 64,198
Machinery and equipment (1) | ​ |  | 167,922 | ​ |  | 155,533
Leasehold improvements | ​ |  | 51,065 | ​ |  | 54,764
Gross property, plant, and equipment | ​ |  | 288,246 | ​ |  | 279,556
Less: accumulated depreciation and amortization | ​ |  | 175,018 | ​ |  | 172,275
Net property, plant, and equipment | ​ | $ | 113,228 | ​ | $ | 107,281

(1) | Machinery and equipment also includes software, furniture and fixtures

​

For the three months ended March 31, 2023 and 2022, depreciation expense was $4.2 million and $3.7 million, respectively.

​

16

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Goodwill

​

Goodwill represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and separately recognized. The following table presents the changes in goodwill balances for the three months ended March 31, 2023:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Gross carrying |  | Accumulated |  | ​
​ | ​ | amount | ​ | impairment | ​ | Net amount
​ |  | (in thousands)
Balance at December 31, 2022 | ​ | $ | 430,331 | ​ | $ | 248,388 | ​ | $ | 181,943
Acquisition | ​ | ​ | 33,021 | ​ | ​ | — | ​ | ​ | 33,021
Balance at March 31, 2023 | ​ | $ | 463,352 | ​ | $ | 248,388 | ​ | $ | 214,964

​

Intangible Assets

​

Intangible assets consist of purchased technology, customer relationships, patents, trademarks and tradenames, licenses, and backlog, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company continues to assess potential triggering events related to the value of its intangible assets and concluded that there were no indicators of impairment during the three months ended March 31, 2023.

​

The components of purchased intangible assets were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, 2023 | ​ | December 31, 2022
​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ |  | Gross |  | Amortization |  | ​ |  | Gross |  | Amortization |  | ​
​ | ​ | Carrying | ​ | and | ​ | Net | ​ | Carrying | ​ | and | ​ | Net
​ | ​ | Amount | ​ | Impairment | ​ | Amount | ​ | Amount | ​ | Impairment | ​ | Amount
​ | ​ | (in thousands)
Technology | ​ | $ | 355,928 | ​ | $ | 318,168 | ​ | $ | 37,760 | ​ | $ | 327,908 | ​ | $ | 316,918 | ​ | $ | 10,990
Customer relationships | ​ | ​ | 146,925 | ​ | ​ | 135,967 | ​ | ​ | 10,958 | ​ | ​ | 146,465 | ​ | ​ | 135,415 | ​ | ​ | 11,050
Trademarks and tradenames | ​ | ​ | 30,910 | ​ | ​ | 29,365 | ​ | ​ | 1,545 | ​ | ​ | 30,910 | ​ | ​ | 29,063 | ​ | ​ | 1,847
Other | ​ |  | 3,746 | ​ |  | 3,693 | ​ |  | 53 | ​ |  | 3,686 | ​ |  | 3,686 | ​ |  | —
Total | ​ | $ | 537,509 | ​ | $ | 487,193 | ​ | $ | 50,316 | ​ | $ | 508,969 | ​ | $ | 485,082 | ​ | $ | 23,887

​

Other intangible assets primarily consist of patents, licenses, and backlog.

17

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

​

Note 5 — Liabilities

​

Accrued Expenses and Other Current Liabilities

​

The components of accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 consist of:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2023 |  | 2022
​ | ​ | (in thousands)
Payroll and related benefits | ​ | $ | 30,257 | ​ | $ | 30,044
Contingent Consideration | ​ | ​ | 9,606 | ​ | ​ | —
Warranty | ​ | ​ | 8,703 | ​ | ​ | 8,601
Operating lease liabilities | ​ | ​ | 3,542 | ​ | ​ | 3,333
Interest | ​ | ​ | 2,520 | ​ | ​ | 2,853
Professional fees | ​ | ​ | 3,242 | ​ | ​ | 2,102
Sales, use, and other taxes | ​ |  | 2,023 | ​ |  | 2,027
Other | ​ |  | 9,597 | ​ |  | 7,071
Total | ​ | $ | 69,490 | ​ | $ | 56,031

​

Warranty

​

Warranties are typically valid for one year from the date of system final acceptance. The Company estimates the costs that may be incurred under the warranty which are determined by analyzing specific product and historical configuration statistics and regional warranty support costs and are affected by product failure rates, material usage, and labor costs incurred in correcting product failures during the warranty period. Unforeseen component failures or exceptional component performance can also result in changes to warranty costs. Changes in product warranty reserves for the three months ended March 31, 2023 include:

​

​ | ​ | ​ | ​
​ | ​ | ​ | (in thousands)
Balance - December 31, 2022 | ​ | $ | 8,601
Warranties issued | ​ |  | 1,678
Addition from Epiluvac acquisition | ​ | ​ | 49
Consumption of reserves | ​ |  | (1,707)
Changes in estimate | ​ |  | 82
Balance - March 31, 2023 | ​ | $ | 8,703

​

Customer Deposits and Deferred Revenue

​

Customer deposits totaled $113.1 million and $110.2 million at March 31, 2023 and December 31, 2022, respectively. Deferred revenue represents amounts billed, other than deposits, in excess of the revenue that can be recognized on a particular contract at the balance sheet date. Changes in deferred revenue were as follows:

​

​ | ​ | ​ | ​
​ | ​ | (in thousands)
Balance - December 31, 2022 |  | $ | 16,990
Deferral of revenue | ​ |  | 5,392
Recognition of unearned revenue | ​ |  | (2,268)
Balance - March 31, 2023 |  | $ | 20,114

​

18

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

As of March 31, 2023, the Company has approximately $232.5 million of remaining performance obligations on contracts with an original estimated duration of one year or more, of which approximately 45% is expected to be recognized within one year, with the remaining amounts expected to be recognized between one to three years. The Company has elected to exclude disclosures regarding remaining performance obligations that have an original expected duration of one year or less.

​

Convertible Senior Notes

​

2023 Notes

​

On January 10, 2017, the Company issued $345.0 million of 2.70% convertible senior unsecured notes due 2023 (the “2023 Notes”). The Company received net proceeds, after deducting underwriting discounts and fees and expenses payable by the Company, of approximately $335.8 million. The 2023 Notes bear interest at a rate of 2.70% per year, payable semiannually in arrears on January 15 and July 15 of each year, commencing on July 15, 2017. The 2023 Notes mature on January 15, 2023, unless earlier purchased by the Company, redeemed, or converted.

​

On May 18, 2020, in connection with the completion of a private offering of $125.0 million aggregate principal amount of 3.75% convertible senior notes due 2027 described below, the Company repurchased and retired approximately $88.3 million in aggregate principal amount of its outstanding 2023 Notes, with a carrying amount of $78.1 million, for approximately $81.2 million of cash.

​

Additionally, on November 11, 2020, the Company entered into a privately negotiated exchange agreement with a holder of its outstanding 2023 Notes, under which the Company agreed to retire $125.0 million in aggregate original principal amount of the 2023 Notes, with a carrying amount of $113.1 million, in exchange for the issuance of $132.5 million in aggregate principal amount of new 3.50% convertible senior notes due 2025 described below, which had a fair value that approximated the principal amount of notes issued.

​

Finally, on November 5, 2021, the Company entered into a privately negotiated note purchase agreement with a holder of its outstanding 2023 Notes, under which the Company agreed to repurchase and retire approximately $111.5 million in aggregate original principal amount of the 2023 Notes, with a carrying amount of $105.5 million, for cash consideration of approximately $115.6 million, and approximately $1.0 million of accrued and unpaid interest.

​

The 2023 notes matured on January 15, 2023 and were paid in cash and settled by the company at that time.

​

2025 Notes

​

On November 17, 2020, as part of the privately negotiated exchange agreement described above, the Company issued $132.5 million of 3.50% convertible senior notes due 2025 (the “2025 Notes”). The 2025 Notes bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, commencing on July 15, 2021. The 2025 Notes mature on January 15, 2025, unless earlier purchased by the Company, redeemed, or converted.

​

2027 Notes

​

On May 18, 2020, the Company completed a private offering of $125.0 million of 3.75% convertible senior notes due 2027 (the “2027 Notes”). The Company received net proceeds of approximately $121.9 million, after deducting underwriting discounts and fees and expenses payable by the Company. Additionally, the Company used approximately $10.3 million of cash to purchase capped calls, discussed below. The 2027 Notes bear interest at a rate of 3.75% per

19

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

year, payable semiannually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes mature on June 1, 2027, unless earlier purchased by the Company, redeemed, or converted.

​

The 2025 Notes and 2027 Notes (collectively, the “Notes”) are unsecured obligations of Veeco and rank senior in right of payment to any of Veeco’s subordinated indebtedness; equal in right of payment to all of Veeco’s unsecured indebtedness that is not subordinated; effectively subordinated in right of payment to any of Veeco’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally subordinated to all indebtedness and other liabilities (including trade payables) of Veeco’s subsidiaries.

​

The Notes are convertible at the option of the holders upon the satisfaction of specified conditions and during certain periods as described below. The initial conversion rates are 41.6667 and 71.5372 shares of the Company’s common stock per $1,000 principal amount of the 2025 Notes and 2027 Notes, respectively, representing initial effective conversion prices of $24.00 and $13.98 per share of common stock, respectively. The conversion rates may be subject to adjustment upon the occurrence of certain specified events.

​

Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding, October 15, 2024 with respect to the 2025 Notes, and October 1, 2026 with respect to the 2027 Notes, only under the following circumstances:

​

| (i) | During any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

​

| (ii) | During the five consecutive business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Veeco’s common stock and the conversion rate on each such trading day;

​

| (iii) | If the Company calls any or all of applicable series of the Notes for redemption at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

​

| (iv) | Upon the occurrence of specified corporate events.

​

For the calendar quarter ended March 31, 2023, the last reported sales price of common stock during the 30 consecutive trading days, based on the criteria outlined in (i) above, was greater than 130% of the conversion price of the 2027 Notes, and as such the 2027 Notes are convertible by the holders until June 30, 2023.

​

Holders may convert their notes at any time, regardless of the foregoing circumstances, on October 15, 2024 with respect to the 2025 Notes, and October 1, 2026 with respect to the 2027 Notes, until the close of business on the business day immediately preceding the respective maturity date.

​

The Notes are recorded as a single unit within liabilities in the consolidated balance sheets as the conversion features within the Notes are not derivatives that require bifurcation and the Notes do not involve a substantial premium. Transaction costs of $9.2 million, $1.9 million, and $3.1 million incurred in connection with the issuance of the 2023 Notes, 2025 Notes, and 2027 Notes, respectively, were recorded as direct deductions from the related debt liabilities and recognized as non-cash interest expense using the effective interest method over the expected terms of the Notes.

​

​

​

20

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

The carrying value of the 2023 Notes, 2025 Notes and 2027 Notes are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | March 31, 2023 | ​ | ​ | December 31, 2022
​ |  | ​ | Principal Amount |  | ​ | Unamortized transaction costs |  | ​ | Net carrying value |  | ​ | Principal Amount |  | ​ | Unamortized debt discount/ transaction costs |  | ​ | Net carrying value
​ | ​ | ​ | (in thousands)
2023 Notes | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | 20,173 | ​ | $ | (4) | ​ | $ | 20,169
2025 Notes | ​ |  | 132,500 | ​ |  | (872) | ​ |  | 131,628 | ​ |  | 132,500 | ​ |  | (990) | ​ |  | 131,510
2027 Notes | ​ | ​ | 125,000 | ​ | ​ | (1,915) | ​ | ​ | 123,085 | ​ | ​ | 125,000 | ​ | ​ | (2,019) | ​ | ​ | 122,981
Net carrying value | ​ | $ | 257,500 | ​ | $ | (2,787) | ​ | $ | 254,713 | ​ | $ | 277,673 | ​ | $ | (3,013) | ​ | $ | 274,660

​

Total interest expense related to the 2023 Notes, 2025 Notes and 2027 Notes is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​ | ​
​ |  | 2023 |  | 2022 |  | ​
​ |  | (in thousands) | ​
Cash Interest Expense |  | ​ |  | ​ | ​ |  | ​ | ​
Coupon interest expense - 2023 Notes | ​ | $ | 23 | ​ | $ | 136 | ​ | ​
Coupon interest expense - 2025 Notes | ​ | ​ | 1,159 | ​ | ​ | 1,159 | ​ | ​
Coupon interest expense - 2027 Notes | ​ | ​ | 1,172 | ​ | ​ | 1,172 | ​ | ​
Non-cash Interest Expense | ​ |  | ​ | ​ |  |  | ​ | ​
Amortization of debt discount/transaction costs- 2023 Notes | ​ |  | 4 | ​ |  | 24 | ​ | ​
Amortization of debt discount/transaction costs- 2025 Notes | ​ | ​ | 117 | ​ | ​ | 113 | ​ | ​
Amortization of debt discount/transaction costs- 2027 Notes | ​ | ​ | 105 | ​ | ​ | 100 | ​ | ​
Total Interest Expense | ​ | $ | 2,580 | ​ | $ | 2,704 | ​ | ​

​

The Company determined the 2025 Notes and 2027 Notes are Level 2 liabilities in the fair value hierarchy and had an estimated fair value at March 31, 2023 of $143.7 and $210.5 million, respectively.

​

Capped Call Transactions

​

In connection with the offering of the 2027 Notes, on May 13, 2020, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”), pursuant to capped call confirmations, covering the total principal amount of the 2027 Notes for an aggregate premium of $10.3 million. The Capped Call Transactions are expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of the 2027 Notes and/or offset any cash payments the Company is required to make in excess of the aggregate principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a cap based on the capped price of the Capped Call Transactions. The Capped Call Transactions exercise price is equal to the initial conversion price of the 2027 Notes, and the capped price of the Capped Call Transactions is approximately $18.46 per share and is subject to certain adjustments under the terms of the capped call confirmations.

​

The Capped Call Transactions are separate transactions entered into by the Company with the capped call counterparties, are not part of the terms of the 2027 Notes and do not change the holders’ rights under the 2027 Notes. Holders of the 2027 Notes do not have any rights with respect to the Capped Call Transactions. The cost of the Capped Call Transactions is not expected to be tax-deductible as the Company did not elect to integrate the Capped Call Transactions into the 2027 Notes for tax purposes. The Company used a portion of the net proceeds from the offering of the 2027 Notes to pay for the Capped Call Transactions, and the cost of the Capped Call Transactions was recorded as a reduction of the Company’s additional paid-in capital in the accompanying consolidated financial statements.

​

21

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Revolving Credit Facility

​

On December 16, 2021, the Company entered into a loan and security agreement providing for a senior secured revolving credit facility in an aggregate principal amount of $150 million (the “Credit Facility”), including a $15 million letter of credit sublimit. The Credit Facility is guaranteed by the Company’s direct material U.S. subsidiaries, subject to customary exceptions. Borrowings under the Credit Facility are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. The Credit Facility has a term of five years, maturing on December 16, 2026, or earlier if certain liquidity measures are not met prior to the 2025 Notes maturing. Subject to certain conditions and the receipt of commitments from the lenders, the Loan and Security Agreement allows for revolving commitments under the Credit Facility to be increased by up to $75 million. The existing lenders under the Credit Facility are entitled, but not obligated, to provide such incremental commitments.

​

Borrowings will bear interest at a floating rate which can be, at the Company’s option, either (a) an alternate base rate plus an applicable rate ranging from 0.50% to 1.25% or (b) a Secured Overnight Financing Rate (“SOFR”) (with a floor of 0.00%) for the specified interest period plus an applicable rate ranging from 1.50% to 2.25%, in each case, depending on the Company’s Secured Net Leverage Ratio (as defined in the Loan and Security Agreement). The Company will pay an unused commitment fee ranging from 0.25% to 0.35% based on unused capacity under the Credit Facility and the Company’s Secured Net Leverage Ratio. The Company may use the proceeds of borrowings under the Credit Facility to pay transaction fees and expenses, provide for its working capital needs and reimburse drawings under letters of credit and for other general corporate purposes.

​

The Loan and Security Agreement contains customary affirmative covenants for transactions of this type, including, among others, the provision of financial and other information to the administrative agent, notice to the administrative agent upon the occurrence of certain material events, preservation of existence, maintenance of properties and insurance, compliance with laws, including environmental laws, the provision of additional guarantees, and an affiliate transactions covenant, subject to certain exceptions. The Loan and Security Agreement contains customary negative covenants, including, among others, restrictions on the ability to merge and consolidate with other companies, incur indebtedness, refinance our existing convertible notes, grant liens or security interests on assets, make investments, acquisitions, loans, or advances, pay dividends, and sell or otherwise transfer assets.

​

The Loan and Security Agreement contains financial maintenance covenants that require the Borrower to maintain an Interest Coverage Ratio (as defined in the Loan and Security Agreement) of not less than 3.00 to 1.00, a Total Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 4.50 to 1.00, and a Secured Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 2.50 to 1.00, in each case, tested at the end of each fiscal quarter commencing with the fiscal quarter ending June 30, 2022. The Loan and Security Agreement also provides for a number of customary events of default, including, among others: payment defaults to the lenders; voluntary and involuntary bankruptcy proceedings; covenant defaults; material inaccuracies of representations and warranties; certain change of control events; material money judgments; and other customary events of default. The occurrence of an event of default could result in the acceleration of obligations and the termination of lending commitments under the Loan and Security Agreement.

​

No amounts were outstanding under the Credit Facility as of March 31, 2023 or December 31, 2022.

​

Other Liabilities

​

Other liabilities at March 31, 2023 and December 31, 2022 included (i) medical and dental benefits for former executives of $1.9 million and $2.0 million, respectively; (ii) asset retirement obligations of $0.9 million and $0.7 million, respectively; and (iii) contingent consideration of $16.5 million as of March 31, 2023.

​

22

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Note 6 — Commitments and Contingencies

​

Leases

​

The Company’s operating leases primarily include real estate leases for properties used for manufacturing, R&D activities, sales and service, and administration, as well as certain equipment leases. Some leases may include options to renew for a period of up to 5 years, while others may include options to terminate the lease. The weighted average remaining lease term of the Company’s operating leases as of March 31, 2023 was 12 years, and the weighted average discount rate used in determining the present value of future lease payments was 5.6%.

​

The following table provides the maturities of lease liabilities at March 31, 2023:

​

​ | ​ | ​ | ​
​ | ​ | Operating
​ |  | Leases
​ | ​ | (in thousands)
Payments due by period: | ​ | ​ | ​
2023 | ​ | $ | 2,782
2024 | ​ | ​ | 4,683
2025 | ​ | ​ | 4,086
2026 | ​ | ​ | 4,053
2027 | ​ | ​ | 3,627
Thereafter | ​ | ​ | 34,246
Total future minimum lease payments | ​ | ​ | 53,477
Less: Imputed interest | ​ | ​ | (16,422)
Total | ​ | $ | 37,055
​ | ​ | ​ | ​
Reported as of March 31, 2023 | ​ | ​ | ​
Accrued expenses and other current liabilities | ​ | $ | 3,542
Long-term operating lease liabilities | ​ | ​ | 33,513
Total | ​ | $ | 37,055

​

Operating lease cost for the three months ended March 31, 2023 and 2022 were $1.4 million and $1.9 million, respectively. Variable lease cost for the three months ended March 31, 2023 and 2022 were $0.3 million and $0.5 million respectfully. Additionally, the Company has an immaterial amount of short-term leases. Operating cash outflows from operating leases for the three months ended March 31, 2023 and 2022 were $1.4 million and $1.9 million, respectively.

​

Receivable Purchase Agreement

​

In December 2020, the Company entered into a receivable purchase agreement with a financial institution to sell certain of its trade receivables from customers without recourse, up to $15.0 million at any point in time. Pursuant to this agreement, the Company sold $8.3 million of receivables during the three months ended March 31, 2023, all of which remained outstanding as of March 31, 2023 as defined in the receivable purchase agreement, and $6.7 million was available under the agreement for additional sales of receivables. The Company did not sell any receivables under this agreement for the three months ended March 31, 2022. The net sale of accounts receivable under the agreement is reflected as a reduction of accounts receivable in the Company’s Consolidated Balance Sheet at the time of sale and any fees for the sale of trade receivables were not material for the periods presented.

​

23

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Purchase Commitments

​

Veeco has purchase commitments of $255.5 million at March 31, 2023, substantially all of which become due within one year.

​

Bank Guarantees

​

Veeco has bank guarantees and letters of credit issued by a financial institution on its behalf as needed. At March 31, 2023, outstanding bank guarantees and standby letters of credit totaled $9.9 million, and unused bank guarantees and letters of credit of $12.4 million were available to be drawn upon.

​

Legal Proceedings

​

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

​

​

​

Note 7 — Equity

​

Statement of Stockholders’ Equity

​

The following tables present the changes in Stockholders’ Equity:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Accumulated |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Accumulated | ​ | Comprehensive | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Deficit | ​ | Income | ​ | Total
​ | ​ | (in thousands)
Balance at December 31, 2022 |  | 51,660 | ​ | $ | 517 | ​ | $ | 1,078,180 | ​ | $ | (501,801) | ​ | $ | 928 | ​ | $ | 577,824
Net income |  | — | ​ |  | — | ​ |  | — | ​ |  | 8,741 | ​ |  | — | ​ |  | 8,741
Other comprehensive income (loss), net of tax |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 476 | ​ |  | 476
Share-based compensation expense |  | — | ​ |  | — | ​ |  | 7,027 | ​ |  | — | ​ |  | — | ​ |  | 7,027
Net issuance under employee stock plans | ​ | 33 | ​ | ​ | — | ​ | ​ | (8,509) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (8,509)
Balance at March 31, 2023 |  | 51,693 | ​ | $ | 517 | ​ | $ | 1,076,698 | ​ | $ | (493,060) | ​ | $ | 1,404 | ​ | $ | 585,559

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Accumulated |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Accumulated | ​ | Comprehensive | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Deficit | ​ | Income | ​ | Total
​ | ​ | (in thousands)
Balance at December 31, 2021 |  | 50,653 | ​ | $ | 507 | ​ | $ | 1,116,921 | ​ | $ | (681,283) | ​ | $ | 1,483 | ​ | $ | 437,628
Cumulative effect of change in accounting principle - adoption of ASU 2020-06 | ​ | — | ​ |  | — | ​ |  | (56,801) | ​ |  | 12,541 | ​ |  | — | ​ |  | (44,260)
Net income |  | — | ​ |  | — | ​ |  | — | ​ |  | 13,330 | ​ |  | — | ​ |  | 13,330
Other comprehensive income (loss), net of tax |  | — | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (822) | ​ |  | (822)
Share-based compensation expense |  | — | ​ |  | — | ​ |  | 4,481 | ​ |  | — | ​ |  | — | ​ |  | 4,481
Net issuance under employee stock plans | ​ | 590 | ​ | ​ | 6 | ​ | ​ | (6,793) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (6,787)
Balance at March 31, 2022 |  | 51,243 | ​ | $ | 513 | ​ | $ | 1,057,808 | ​ | $ | (655,412) | ​ | $ | 661 | ​ | $ | 403,570

​

24

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Accumulated Other Comprehensive Income (“AOCI”)

​

The following table presents the changes in the balances of each component of AOCI, net of tax:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Unrealized | ​ | ​ | ​
​ | ​ | ​ | ​ | Gains (Losses) | ​ | ​ | ​
​ | ​ | Foreign | ​ | on Available | ​ | ​ | ​
​ | ​ | Currency | ​ | for Sale | ​ | ​ | ​
​ |  | Translation |  | Securities |  | Total
​ | ​ | (in thousands)
Balance - December 31, 2022 | ​ | $ | 1,773 | ​ | $ | (845) | ​ | $ | 928
Other comprehensive income (loss) | ​ |  | 6 | ​ |  | 470 | ​ |  | 476
Balance - March 31, 2023 | ​ | $ | 1,779 | ​ | $ | (375) | ​ | $ | 1,404

​

There were minimal reclassifications from AOCI into net income for the three months ended March 31, 2023 and 2022.

​

Note 8 — Share-based Compensation

​

Restricted share awards are issued to employees and to members of our board of directors that are subject to specified restrictions and a risk of forfeiture. The restrictions typically lapse over one to four years and may entitle holders to dividends and voting rights. Other types of share-based compensation include performance share awards, performance share units, and restricted share units (collectively with restricted share awards, “restricted shares”), as well as options to purchase common stock.

​

Share-based compensation expense was recognized in the following line items in the Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​ | ​
​ |  | 2023 |  | 2022 |  |
​ | ​ | (in thousands) | ​
Cost of sales |  | $ | 1,451 |  | $ | 938 |  |
Research and development | ​ | ​ | 2,089 | ​ | ​ | 1,257 | ​ | ​
Selling, general, and administrative | ​ | ​ | 3,487 | ​ | ​ | 2,286 | ​ | ​
Total | ​ | $ | 7,027 | ​ | $ | 4,481 | ​ | ​

​

For the three months ended March 31, 2023, equity activity related to stock options was as follows:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | Number of | ​ | Average
​ |  | Shares |  | Exercise Price
​ | ​ | (in thousands) | ​ | ​ | ​
Balance - December 31, 2022 | ​ | 177 | ​ | $ | 30.94
Expired | ​ | (1) | ​ | ​ | 30.47
Balance - March 31, 2023 | ​ | 176 | ​ | ​ | 30.94

​

25

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

For the three months ended March 31, 2023, equity activity related to non-vested restricted shares and performance shares was as follows:

​

​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | Number of | ​ | Grant Date
​ | ​ | Shares | ​ | Fair Value
​ | ​ | (in thousands) | ​ | ​ | ​
Balance - December 31, 2022 | ​ | 2,496 | ​ | $ | 23.83
Granted | ​ | 1,022 | ​ | ​ | 22.90
Performance award adjustments | ​ | 183 | ​ | ​ | 10.59
Vested | ​ | (1,012) | ​ | ​ | 16.22
Forfeited | ​ | (14) | ​ | ​ | 22.46
Balance - March 31, 2023 | ​ | 2,675 | ​ | ​ | 25.46

​

​

Note 9 — Income Taxes

​

Income taxes are estimated for each of the jurisdictions in which the Company operates. Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. Realization of net deferred tax assets is dependent on future taxable income.

​

At the end of each interim reporting period, the effective tax rate is aligned with expectations for the full year. This estimate is used to determine the income tax provision on a year-to-date basis and may change in subsequent interim periods.

​

Income before income taxes and income tax expense (benefit) for the three months ended March 31, 2023 and 2022 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, |
​ |  | 2023 |  | 2022 |
​ | ​ | (in thousands, except percentages) |
Income before income taxes | ​ | $ | 9,004 | ​ | $ | 13,714 | ​
Income tax expense (benefit) |  | $ | 263 |  | $ | 384 | ​
Effective tax rate |  | ​ | 2.93% |  | ​ | 2.80% | ​

​

The Company’s tax expense for the three months ended March 31, 2023 was $0.3 million, compared to $0.4 million for the comparable prior period. For the three months ended March 31, 2023, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall. Additionally, the effective tax rate was also favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. For the three months ended March 31, 2022, the effective tax rate was lower than the U.S. statutory tax rate primarily related to changes in the valuation allowance of deferred tax assets in the U.S.

​

Note 10 — Segment Reporting and Geographic Information

​

Veeco operates and measures its results in one operating segment and therefore has one reportable segment: the development, manufacture, sales, and support of semiconductor and thin film process equipment primarily sold to make electronic devices.

​

26

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Veeco serves the following four end-markets:

​

Semiconductor

​

The Semiconductor market refers to early process steps in logic and memory applications where silicon wafers are processed. There are many different process steps in forming patterned wafers, such as deposition, etching, masking, and doping, where the microchips are created but remain on the silicon wafer. This market includes mask blank production for extreme ultraviolet (“EUV”) lithography, as well as Advanced Packaging, which refers to a portfolio of wafer-level assembly technologies that enable improved performance of electronic products, such as smartphones, high-end servers, and graphical processors.

​

Compound Semiconductor

​

The Compound Semiconductor market includes Photonics, Power Electronics, RF Filters and Amplifiers, and Solar applications. Photonics refers to light source technologies and laser-based solutions for 3D sensing, datacom and telecom applications. This includes micro-LED, laser diodes, edge emitting lasers and vertical cavity surface emitting lasers (“VCSELs”). Power Electronics refers to semiconductor devices such as rectifiers, inverters and converters for the control and conversion of electric power in applications such as fast or wireless charging of consumer electronics and automotive applications. RF power amplifiers and filters (including surface acoustic wave (“SAW”) and bulk acoustic wave (“BAW”) filters) are used in 5G communications infrastructure, smartphones, tablets, and mobile devices. They make use of radio waves for wireless broadcasting and/or communications. Solar refers to power obtained by harnessing the energy of the sun through the use of compound semiconductor devices such as photovoltaics.

​

Data Storage

​

Data Storage refers to the Hard Disk Drive (“HDD”) market, for which our systems enable customers to manufacture thin film magnetic heads for hard disk drives as part of large capacity storage applications.

​

Scientific & Other

​

Scientific & Other refers to advanced materials research and a range of manufacturing applications including optical coatings (laser mirrors, optical filters, and anti-reflective coatings).

​

27

Table of Contents

Veeco Instruments Inc. and Subsidiaries

Notes to the Consolidated Financial Statements - continued

(unaudited)

​

Sales by end-market and geographic region for the three months ended March 31, 2023 and 2022 were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, | ​
​ |  | 2023 | ​ | 2022 |
​ | ​ | (in thousands) | ​
Sales by end-market | ​ | ​ | ​ | ​ | ​ | ​ | ​
Semiconductor | ​ | $ | 93,107 | ​ | $ | 77,620 | ​
Compound Semiconductor | ​ | ​ | 21,159 | ​ | ​ | 37,109 | ​
Data Storage | ​ |  | 21,514 | ​ |  | 21,595 | ​
Scientific & Other | ​ |  | 17,724 | ​ |  | 20,102 | ​
Total | ​ | $ | 153,504 | ​ | $ | 156,426 | ​
Sales by geographic region | ​ | ​ | ​ | ​ | ​ | ​ | ​
United States | ​ | $ | 31,011 | ​ | $ | 47,471 | ​
EMEA(1) | ​ | ​ | 22,947 | ​ | ​ | 21,425 | ​
China | ​ | ​ | 60,747 | ​ | ​ | 30,381 | ​
Rest of APAC | ​ | ​ | 38,744 | ​ | ​ | 56,922 | ​
Rest of World | ​ |  | 54 | ​ |  | 227 | ​
Total | ​ | $ | 153,504 | ​ | $ | 156,426 | ​

(1) | EMEA consists of Europe, the Middle East, and Africa

For geographic reporting, sales are attributed to the location in which the customer facility is located.

​

​

​

​

​

28

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

​

Cautionary Statement Regarding Forward Looking Statements

​

Our discussion below constitutes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “targets,” “plans,” “intends,” “will,” and similar expressions related to the future are intended to identify forward-looking statements. All forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from projected results. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made.

​

Executive Summary

​

We are an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, CVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

​

Business Update

​

Macroeconomic challenges across the industry have been well publicized, including supply chain constraints, an inflationary and high-interest rate environment with a potential recession ahead, new China-export regulations, uncertainty in the banking industry, and a forecasted decline in the semiconductor and related markets due to softness in consumer, smartphone and PC applications, all of which are contributing to a difficult environment with increased uncertainty.

​

Longer lead times and parts shortages and allocations have required that we plan further ahead than usual, and we have undertaken efforts to increase our purchase commitments to secure critical components in a timely manner. Although on time deliveries by suppliers have improved, material lead times remain elevated and continue to be a challenge with respect to our supply chain, limiting our ability to fulfill some of our customers’ demands in a timely manner, as many of our peers have also been experiencing. Although we are seeing some signs that lead times could improve in the second half of the year, we expect supply shortages and related challenges to persist throughout 2023, and we continue to monitor our supply chain and work with our suppliers to identify and mitigate potential gaps in an effort to ensure continuity of supply. We also continue to experience increasing labor, logistics, and material costs, creating gross margin pressures.

​

We have seen a slow-down in certain shorter lead time products such as wet processing, advanced packaging lithography, and spare parts and upgrades, as well as instances where customers have requested order cancellations, delayed shipments, or delayed payments. Consequently, we are monitoring the situation very closely and have been taking early actions to limit the pace at which we increase spending while maintaining our growth trajectory.

​

Furthermore, the US Department of Commerce, Bureau of Industry and Security (“BIS”), issued China-export regulations on October 7, 2022 which broadened the requirements under which export licenses will be required, with a presumption of denial as to their issuance. In addition, certain China-based companies were added to the BIS Unverified List, and changes have been made to the BIS Entity List, further restricting sales to the named entities. Recent order activity has led to significant backlog in China, some of which may be subject to these regulations. While the export regulation landscape is fluid and evolving, we believe at this time that the substantial majority of this backlog will not be negatively affected by the new regulations. We anticipate our order backlog for China customers to decline in the second half of 2023 as we deliver these systems in the first half of the year.

​

While we work to overcome these macroeconomic challenges, we continue to serve our customers in the following four end-markets: Semiconductor; Compound Semiconductor; Data Storage; and Scientific & Other.

​

29

Table of Contents

Sales in the Semiconductor market grew 20% year-over-year and declined 1% sequentially in Q1 2023 driven by our laser annealing systems for trailing node logic devices. We continue to build momentum for our laser annealing solutions at advanced node logic customers by winning application steps. We recently announced the receipt of multiple orders for our LSA systems that are qualified for advanced nodes for a Tier 1 logic supplier. While our growth strategy is predominately focused on shipping systems for advanced node logic and memory applications we have also been receiving orders and shipping systems for trailing node applications in China and other regions. In memory we introduced laser annealing to the market and have leveraged a successful evaluation at a DRAM manufacturer into recently placed multiple orders for high volume production of DRAM devices. The ongoing adoption of EUV Lithography for advanced node semiconductor manufacturing continues to drive demand for our Ion Beam mask blank systems. Additionally, our lithography systems for Advanced Packaging are aligned with packaging approaches such as fan out wafer level packaging and other advanced packaging applications, while our wet processing systems are used for Photo Resist Strip and Solvent Cleans. We are currently seeing softness in our Advanced Packaging Lithography and wet processing businesses due to declining consumer electronics demand. Overall, our technology and market strategy are well aligned with trends such as artificial intelligence, mobile connectivity and high-performance computing that drive the Semiconductor market. Given recent order activity and current backlog in the Semiconductor market, we expect revenue in 2023 to outpace wafer fab equipment spending growth, which is the prevailing consensus view has forecasted to be down 15-25% or more in 2023.

​

We address the Compound Semiconductor market with a broad portfolio of technologies, including Wet Processing and MOCVD, along with MBE and Ion Beam, all of which have been developed to support emerging applications such as 5G driven RF device/filter manufacturing, GaN power electronics, and photonics applications including edge-emitting lasers, specialty LEDs and micro-LEDs. Sales in the Compound Semiconductor market in Q1 2023 declined as compared to the prior quarter and comparable prior quarter. In Q1 2023, we shipped systems for photonics applications. We continue to invest for future growth in the Compound Semiconductor market in areas like power electronics and Micro-LEDs. Power electronics markets are served by GaN equipment, and also by SiC epitaxy equipment. We are working to penetrate the GaN power market, which is driven by applications such as wireless charging in consumer electronics. In addition to our GaN system offerings, on January 31st, 2023 Veeco acquired SiC technology to address the high-growth SiC power epitaxy equipment market, which is driven by electric vehicles. With this acquisition, Veeco is accelerating its entry into this market, and expects revenue starting in 2024.

​

Sales in the Data Storage market in Q1 2023 increased from prior quarter while remaining flat quarter over comparable prior year period. Demand for our Ion Beam products is driven by cloud-based storage. Hard disk drive manufacturers are manufacturing drives with an increasing number of magnetic heads and they are introducing advanced technologies which require increased capital intensity. With data proliferation forecasted to continue to grow, and based on orders we received in 2022 and into 2023, we expect revenue growth in 2023.

​

Sales in the Scientific & Other market are largely driven by sales to governments, universities, and research institutions. We address the Scientific & Other market with several technologies, including MBE, ALD, MOCVD, Wet Processing, & IBD/IBE, which support scientific, optical coating and other applications, such as Micro-Electromechanical Systems (MEMS) applications. While revenue was down year-over-year and from the prior quarter, we expect sales in this market to grow in the long run, in line with GDP.

​

Overall, based on our current visibility supported by our backlog, we continue to expect total 2023 revenue to be in the range of $630 million to $670 million.

30

Table of Contents

​

Results of Operations

​

For the three months ended March 31, 2023 and 2022

​

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2023 and 2022 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​ | Change | ​
​ | ​ | 2023 | ​ | ​ | 2022 | ​ | ​ | Period to Period | ​
​ | ​ | (dollars in thousands) | ​
Net sales |  | $ | 153,504 |  | 100% | ​ | ​ | $ | 156,426 |  | 100% | ​ | ​ | $ | (2,922) |  | (2)% | ​ |
Cost of sales | ​ |  | 91,487 |  | 60% | ​ | ​ |  | 90,413 |  | 58% | ​ | ​ |  | 1,074 |  | 1% | ​ | ​
Gross profit | ​ |  | 62,017 |  | 40% | ​ | ​ |  | 66,013 |  | 42% | ​ | ​ |  | (3,996) |  | (6)% | ​ | ​
Operating expenses, net: | ​ |  |  |  |  | ​ | ​ |  |  |  | ​ | ​ | ​ |  |  |  | ​ | ​ | ​
Research and development | ​ |  | 27,562 |  | 18% | ​ | ​ |  | 24,117 |  | 15% | ​ | ​ |  | 3,445 |  | 14% | ​ | ​
Selling, general, and administrative | ​ |  | 22,627 |  | 15% | ​ | ​ |  | 22,894 |  | 15% | ​ | ​ |  | (267) |  | (1)% | ​ | ​
Amortization of intangible assets | ​ |  | 2,111 |  | 1% | ​ | ​ |  | 2,504 |  | 2% | ​ | ​ |  | (393) |  | (16)% | ​ | ​
Other operating expense (income), net | ​ |  | (89) |  | - | ​ | ​ |  | (19) |  | - | ​ | ​ |  | (70) |  | * | ​ | ​
Total operating expenses, net | ​ |  | 52,211 |  | 34% | ​ | ​ |  | 49,496 |  | 32% | ​ | ​ |  | 2,715 |  | 5% | ​ | ​
Operating income | ​ |  | 9,806 |  | 6% | ​ | ​ |  | 16,517 |  | 11% | ​ | ​ |  | (6,711) |  | (41)% | ​ | ​
Interest income (expense), net | ​ |  | (802) |  | (1)% | ​ | ​ |  | (2,803) |  | (2)% | ​ | ​ |  | 2,001 |  | (71)% | ​ | ​
Income before income taxes | ​ |  | 9,004 |  | 6% | ​ | ​ |  | 13,714 |  | 9% | ​ | ​ |  | (4,710) |  | (34)% | ​ | ​
Income tax expense (benefit) | ​ |  | 263 |  | - | ​ | ​ |  | 384 |  | - | ​ | ​ |  | (121) |  | (32)% | ​ | ​
Net income | ​ | $ | 8,741 |  | 6% | ​ | ​ | $ | 13,330 |  | 9% | ​ | ​ | $ | (4,589) |  | (34)% | ​ | ​

* | Not meaningful

Net Sales

The following is an analysis of sales by market and by region:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​ | Change |  | ​
​ | ​ | 2023 | ​ | ​ | 2022 | ​ | ​ | Period to Period |  | ​
​ | ​ | (dollars in thousands) |  | ​
Sales by end-market |  | ​ |  |  |  | ​ | ​ | ​ |  |  |  | ​ | ​ | ​ |  |  |  | ​ |
Semiconductor | ​ | $ | 93,107 |  | 60% | ​ | ​ | $ | 77,620 |  | 49% | ​ | ​ | $ | 15,487 |  | 20% | ​ | ​
Compound Semiconductor | ​ |  | 21,159 |  | 14% | ​ | ​ |  | 37,109 |  | 24% | ​ | ​ |  | (15,950) |  | (43)% | ​ | ​
Data Storage | ​ |  | 21,514 |  | 14% | ​ | ​ |  | 21,595 |  | 14% | ​ | ​ |  | (81) |  | (0)% | ​ | ​
Scientific & Other | ​ |  | 17,724 |  | 12% | ​ | ​ |  | 20,102 |  | 13% | ​ | ​ |  | (2,378) |  | (12)% | ​ | ​
Total | ​ | $ | 153,504 |  | 100% | ​ | ​ | $ | 156,426 |  | 100% | ​ | ​ | $ | (2,922) |  | (2)% | ​ | ​
Sales by geographic region | ​ |  |  |  |  | ​ | ​ |  |  |  |  | ​ | ​ |  |  |  | ​ | ​ | ​
United States | ​ | $ | 31,011 |  | 20% | ​ | ​ | $ | 47,471 |  | 30% | ​ | ​ | $ | (16,460) |  | (35)% | ​ | ​
EMEA | ​ |  | 22,947 |  | 15% | ​ | ​ |  | 21,425 |  | 14% | ​ | ​ |  | 1,522 |  | 7% | ​ | ​
China | ​ | ​ | 60,747 | ​ | 40% | ​ | ​ | ​ | 30,381 | ​ | 19% | ​ | ​ | ​ | 30,366 |  | 100% | ​ | ​
Rest of APAC | ​ |  | 38,744 |  | 25% | ​ | ​ |  | 56,922 |  | 37% | ​ | ​ |  | (18,178) |  | (32)% | ​ | ​
Rest of World | ​ |  | 54 |  | - | ​ | ​ |  | 227 |  | - | ​ | ​ |  | (173) |  | * | ​ | ​
Total | ​ | $ | 153,504 |  | 100% | ​ | ​ | $ | 156,426 |  | 100% | ​ | ​ | $ | (2,922) |  | (2)% | ​ | ​

* | Not meaningful

​

31

Table of Contents

Sales decreased for the three months ended March 31, 2023 against the comparable prior year period in the Compound Semiconductor and Scientific & Other markets, partially offset by an increase in the Semiconductor market. By geography, sales increased in the China and EMEA regions. Sales in the Rest of APAC region for the three months ended March 31, 2023 included sales in Taiwan and Thailand of $18.0 million and $8.4 million respectively. Sales in the Rest of APAC region for the three months ended March 31, 2022 included sales in Singapore and Taiwan of $23.9 million and $17.2 million, respectively. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate.

​

Gross Profit

​

For the three months ended March 31, 2023, gross profit decreased against the comparable prior period due to a decrease in sales volume and gross margins. Gross margins decreased principally due to product mix of sales in the period, as well as increased logistics costs, partially offset by favorable operations spend activity. We expect our gross margins to fluctuate each period due to product mix and other factors.

​

Research and Development

​

The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses increased for the three months ended March 31, 2023 against the comparable prior period primarily due to personnel-related expenses as we invest in new research and development and additional applications for our technology in order to be well-positioned to capitalize on emerging global megatrends and support longer term growth in Semiconductor and Compound Semiconductor markets.

​

Selling, General, and Administrative

​

Selling, general, and administrative expenses remained flat for the three months ended March 31, 2023 against the comparable prior period. Given the uncertainty regarding the impacts on our business resulting from the general macroeconomic environment, we are focused on the proactive management of expenses.

​

Amortization Expense

​

Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets.

Interest Income (Expense)

​

We recorded net interest expense of $0.8 million for the three months ended March 31, 2023, compared to $2.8 million for the comparable prior year period. The decrease in net interest expense was primarily related to an increase of interest income of approximately $2.0 million due to a more favorable interest rate environment for the three months ended March 31, 2023, against the comparable prior year period.

​

Income Taxes

​

At the end of each interim reporting period, we estimate the effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

​

Our tax expense for the three months ended March 31, 2023, was $0.3 million, compared to $0.4 million for the period ended March 31, 2022. For the three months ended March 31, 2023, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall. Additionally, the effective tax rate was also favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and

32

Table of Contents

research and development tax credits. For the three months ended March 31, 2022, the effective tax rate was lower than the U.S. statutory tax rate primarily related to changes in the valuation allowance of deferred tax assets in the U.S.

​

Liquidity and Capital Resources

​

Our cash and cash equivalents, restricted cash, and short-term investments are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2023 |  | 2022
​ | ​ | (in thousands)
Cash and cash equivalents | ​ | $ | 140,721 | ​ | $ | 154,925
Restricted cash | ​ |  | 476 | ​ |  | 547
Short-term investments | ​ |  | 112,170 | ​ |  | 147,488
Total | ​ | $ | 253,367 | ​ | $ | 302,960

​

At March 31, 2023 and December 31, 2022, cash and cash equivalents of $30.9 million and $28.4 million, respectively, were held outside the United States. As of March 31, 2023, we had $18.7 million of accumulated undistributed earnings generated by our non-U.S. subsidiaries for which the U.S. tax has previously been provided. Approximately $8.1 million of undistributed earnings will be subject to foreign withholding taxes if distributed back to the United States and we accrued $0.9 million for foreign withholding taxes for the undistributed earnings.

​

We believe that our projected cash flow from operations, combined with our cash and short-term investments, will be sufficient to meet our projected working capital requirements, contractual obligations, and other cash flow needs for the next twelve months, including scheduled interest payments on our convertible senior notes, purchase commitments, and payments in respect of operating leases.

​

A summary of the cash flow activity for the three months ended March 31, 2023 and 2022 is as follows:

​

Cash Flows from Operating Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, |
​ |  | 2023 |  | 2022 |
​ | ​ | (in thousands) | ​
Net income | ​ | $ | 8,741 | ​ | $ | 13,330 | ​
Non-cash items: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 6,276 | ​ |  | 6,240 | ​
Non-cash interest expense | ​ |  | 226 | ​ |  | 238 | ​
Deferred income taxes | ​ |  | 191 | ​ |  | (16) | ​
Share-based compensation expense | ​ |  | 7,027 | ​ |  | 4,481 | ​
Changes in operating assets and liabilities | ​ |  | (8,543) | ​ |  | 515 | ​
Net cash provided by (used in) operating activities | ​ | $ | 13,918 | ​ | $ | 24,788 | ​

​

Net cash provided by operating activities was $13.9 million for the three months ended March 31, 2023 and was due to net income of $8.7 million and adjustments for non-cash items of $13.7 million, partially offset by a decrease in cash flow from changes in operating assets and liabilities of $8.5 million. The changes in operating assets and liabilities were largely attributable to 1) increases in inventories; partially offset by 2) increases in accounts payable and accrued expenses; and 3) increases in customer deposits and deferred revenue.

​

33

Table of Contents

Cash Flows from Investing Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​
​ |  | 2023 |  | 2022 |
​ | ​ | (in thousands) | ​
Acquisitions of businesses, net of cash acquired | ​ | $ | (30,373) | ​ | $ | — | ​
Capital expenditures | ​ | $ | (6,946) | ​ | $ | (10,918) | ​
Changes in investments, net | ​ |  | 36,557 | ​ |  | (238) | ​
Net cash provided by (used in) investing activities | ​ | $ | (762) | ​ | $ | (11,156) | ​

​

The cash used in investing activities during the three months ended March 31, 2023 and 2022 was primarily attributable to the net cash used in the acquisition of Epiluvac, as well as capital expenditures, partially offset by net investment activity. We experienced a high level of capital expenditures during 2022 associated with the continued build-out of our newly leased facility in San Jose, California, which is substantially complete at this time.

Cash Flows from Financing Activities

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​
​ |  | 2023 |  | 2022 |
​ | ​ | (in thousands) | ​
Repayment of 2023 Notes | ​ | $ | (20,173) | ​ | ​ | — | ​
Settlement of equity awards, net of withholding taxes | ​ | ​ | (7,268) | ​ | $ | (5,789) | ​
Net cash provided by (used in) financing activities | ​ | $ | (27,441) | ​ | $ | (5,789) | ​

​

The cash used in financing activities for the three months ended March 31, 2023 was related to the repayment of the 2023 Notes, as well as cash used to settle taxes related to employee equity programs, partially offset by cash received under the Employee Stock Purchase Plan.

​

Convertible Senior Notes

​

We have $132.5 million outstanding principal balance of 3.50% convertible senior notes that bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, and mature on January 15, 2025, unless earlier purchased by the Company, redeemed, or converted. In addition, we have $125.0 million outstanding principal balance of 3.75% convertible senior notes that bear interest at a rate of 3.75% per year, payable semiannually in arrears on June 1 and December 1 of each year, and mature on June 1, 2027, unless earlier purchased by the Company, redeemed, or converted. The 2027 Notes are currently convertible by shareholders until June 30, 2023.

​

We believe that we have sufficient capital resources and cash flows from operations to support scheduled interest payments on these debts. In addition, we have access to a $150.0 million revolving credit facility (including an ability to request an additional $75.0 million, for a total commitment of no more than $225.0 million) to provide for our working capital needs and reimburse drawings under letters of credit and for other general corporate purposes. The Company has no immediate plans to draw down on the facility, which expires in December of 2026. Interest under the facility is variable based on the Company’s secured net leverage ratio and is expected to bear interest based on SOFR plus a range of 150 to 225 basis points, if drawn. There is a yearly commitment fee of 25 to 35 basis points, based on the Company’s secured net leverage ratio, charged on the unused portion of the Facility.

​

Contractual Obligations and Commitments

​

We have commitments under certain contractual arrangements to make future payments for goods and services. These contractual arrangements secure the rights to various assets and services to be used in the future in the normal course of business. We expect to fund these contractual arrangements with cash generated from operations in the normal course of business.

​

34

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

​

Interest Rate Risk

​

Our exposure to market rate risk for changes in interest rates primarily relates to our investment portfolio. We centrally manage our investment portfolios considering investment opportunities and risks, tax consequences, and overall financing strategies. Our investment portfolio includes fixed-income securities with a fair value of approximately $112.2 million at March 31, 2023. These securities are subject to interest rate risk and, based on our investment portfolio at March 31, 2023, a 100 basis point increase in interest rates would result in a decrease in the fair value of the portfolio of $0.4 million. While an increase in interest rates may reduce the fair value of the investment portfolio, we will not realize the losses in the Consolidated Statements of Operations unless the individual fixed-income securities are sold prior to recovery or the loss is determined to be other-than-temporary.

​

Currency Exchange Risk

​

We conduct business on a worldwide basis and, as such, a portion of our revenues, earnings, and net investments in foreign affiliates is exposed to changes in currency exchange rates. The economic impact of currency exchange rate movements is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions, and other factors. These changes, if material, could cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

​

Changes in currency exchange rates could affect our foreign currency denominated monetary assets and liabilities and forecasted cash flows. We may enter into monthly forward derivative contracts from time to time with the intent of mitigating a portion of this risk. We only use derivative financial instruments in the context of hedging and not for speculative purposes and have not historically designated our foreign exchange derivatives as hedges. Accordingly, changes in fair value from these contracts are recorded as “Other, net” in our Consolidated Statements of Operations. We execute derivative transactions with highly rated financial institutions to mitigate counterparty risk.

​

Our net sales to customers located outside of the United States represented approximately 80% and 70% of our total net sales for the three months ended March 31, 2023 and 2022, respectively. We expect that net sales to customers outside the United States will continue to represent a large percentage of our total net sales. Our sales denominated in currencies other than the U.S. dollar represented approximately 3% of total net sales for both the three months ended March 31, 2023 and 2022.

​

A 10% change in foreign exchange rates would have an immaterial impact on the consolidated results of operations since most of our sales outside the United States are denominated in U.S. dollars.

​

Item 4. Controls and Procedures

​

Evaluation of Disclosure Controls and Procedures

​

Our principal executive and financial officers have evaluated and concluded that our disclosure controls and procedures are effective as of March 31, 2023. The disclosure controls and procedures are designed to ensure that the information required to be disclosed in this report filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to our principal executive and financial officers as appropriate to allow timely decisions regarding required disclosure.

​

Changes in Internal Control Over Financial Reporting

​

On January 31, 2023, we completed the acquisition of Epiluvac AB and are integrating the acquired business into our overall internal control over financial reporting process. Management is in the process of assessing the internal control over financial reporting and is implementing or revising internal controls where necessary. See Note 3 to the

35

Table of Contents

Consolidated Financial Statements – Business Combinations, for further details. There were no other changes in internal control for the quarter ended March 31, 2023 that have materially affected or are reasonably likely to materially affect internal control over financial reporting.

​

PART II—OTHER INFORMATION

​

Item 1. Legal Proceedings

​

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

​

Item 1A. Risk Factors

​

Information regarding risk factors appears in the Safe Harbor Statement at the beginning of this quarterly report on Form 10-Q, in Part I — Item 1A of our 2022 Form 10-K. There have been no material changes from the risk factors previously disclosed,

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

​

None.

​

Item 3. Defaults Upon Senior Securities

​

None.

​

Item 4. Mine Safety Disclosures

​

Not Applicable.

​

Item 5. Other Information

​

None.

​

36

Table of Contents

Item 6. Exhibits

​

Unless otherwise indicated, each of the following exhibits has been filed with the Securities and Exchange Commission by Veeco under File No. 0-16244.

​

Exhibit | ​ | ​ | ​ | Incorporated by Reference | ​ | Filed or Furnished
Number |  | Exhibit Description |  | Form |  | Exhibit |  | Filing Date |  | Herewith
| ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
10.1 | ​ | Form of Notice of Performance Restricted Stock Unit Award and related terms and conditions pursuant to the Veeco 2019 Stock Incentive plan, effective March 2023. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
10.2 | ​ | Form of Notice of Restricted Stock Unit Award and related terms and conditions pursuant to Veeco 2019 Stock Incentive Plan, effective March 2023. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
31.1 | ​ | Certification of Chief Executive Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
31.2 | ​ | Certification of Chief Financial Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
32.1 | ​ | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
32.2 | ​ | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
101.INS | ​ | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | *
101.XSD | ​ | XBRL Schema. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **
101.PRE | ​ | XBRL Presentation. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **
101.CAL | ​ | XBRL Calculation. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **
101.DEF | ​ | XBRL Definition. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **
101.LAB | ​ | XBRL Label. | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ​ | ​ | ​ | ​ | ​ | ​ | ​ | **

​

​ ​​ ​​ ​​

* Filed herewith

** Filed herewith electronically

​

37

Table of Contents

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 8, 2023.

​

​ |  |
​ | Veeco Instruments Inc.
​ | ​
​ | By: | /s/ WILLIAM J. MILLER, Ph.D.
​ | ​ | William J. Miller, Ph.D.
​ | ​ | Chief Executive Officer
​ | ​ | ​
​ | By: | /s/ JOHN P. KIERNAN
​ | ​ | John P. Kiernan
​ | ​ | Senior Vice President and Chief Financial Officer

​

​

​

38